COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

Apollo Pact Inc
Brooklyn, NY · EIN 851837133 · Form 990 · FY2025 · NTEE F70 · Mental Health & Crisis Intervention · Small ($100K-$1M) · apollopact.org
revenue
$202K
expenses
$148K
net assets
$169K
employees
0
volunteers
4
program ratio
73%
mission · from form 990

Engage in advocacy efforts. Integrate former study participants from FDA clinical trials studying psychedelic compounds. Information Sharing: Collaborate with academic researchers. Identify FDA, Address the mental illness epidemic by rely

profile · synthesized from sources

Apollo Pact Inc is a patient advocacy nonprofit focused on advancing psychedelic medicine for mental health and substance use disorders. The organization educates policymakers and the public about FDA-regulated clinical research and supports integration for participants in psychedelic trials. It amplifies patient voices in policy discussions, particularly through its engagement with the Congressional PATH Caucus.

named programs · 2 · from sources

What they call their work

PATH Caucus Support
Provides patient advocacy and educational support to the Congressional Psychedelics Advancing Therapies (PATH) Caucus through organizing briefings, amplifying patient voices, and informing legislative discussions on psychedelic-assisted therapies.
Research Participant Rights Initiative
Educates clinical trial participants about their rights, including informed consent, privacy, withdrawal, and access to study findings, with a focus on psychedelic research.
activities · 2 groups

What they do

  • Psychedelic Therapy Support & Advocacy 5 activities
    • Advocacy to address the mental illness epidemic through psychedelic policy
      Engages in policy advocacy aimed at addressing the mental illness epidemic by promoting evidence-based approaches involving psychedelic medicine.
    • Capitol Hill advocacy for psychedelic therapies
      Organizes and leads briefings on Capitol Hill to educate members of Congress and staff on findings from FDA-regulated psychedelic clinical trials and amplifies patient and participant voices in policy discussions.
    • Conducting clinical research on psychedelic therapies
      Conducted a randomized controlled trial on psilocybin for alcohol use disorder at New York University, contributing to clinical understanding and personal recovery from treatment-resistant alcoholism.
    • Education and support for patients exploring psychedelic therapy
      Provides education and direct support to patients navigating psychedelic therapy research and treatment options, including integration of individuals with lived experience from FDA-regulated clinical trials.
    • Public education on psychedelic medicine
      Advances public understanding of psychedelic medicine through educational resources, collaboration with academic researchers, and dissemination of scientific information.
  • Uncategorized 1 activity
    • Advocacy for participant rights in psychedelic research
      Provides educational resources and guidance to clinical research participants on their rights and how to address study-specific concerns, promoting ethical research practices.
financials · form 990 · fy2025
revenue
Total revenue$202K
Contributions & grants$202K100%
Program service revenue$00%
Investment income$00%
Other revenue$0
expenses
Total expenses$148K
Program expenses73%
Admin / overhead27%
Fundraising0%
Salaries & benefits$112K
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$169K
Cash$169K
Investments$0
Liabilities$0
Net assets$169K
Liquid reserves13.7 mo
5 years on record · 2020–2025 · YoY revenue +316.5%
leadership · form 990 part vii · fy2025

Who runs it

paid leadership · 2
NameTitleHours/wkCompensation
Jonathan Steven Kostas President 30 $72K
Marian Walters Chair 10 $40K
relationships · 14

Who they work with

  • Association for Prescription Psychedelics Network — Jon Kostas serves as Executive Director of the Association for Prescription Psychedelics, representing clinical developers of psychedelic therapies.
  • Congressional Psychedelics Advancing Therapies (PATH) Caucus Partner — Apollo Pact serves as the primary patient advocacy organization supporting the PATH Caucus.
  • Dana Farber Cancer Institute Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, funds research on psilocybin for depressed terminally ill patients at this Harvard-affiliated institution.
  • Emory University School of Medicine Partner — Scientific advisor Dr. Roman Palitsky is a Research Psychologist at Emory University School of Medicine.
  • Heffter Research Institute Partner — Scientific advisor Dr. George R. Greer is a co-founder and former Medical Director of the Heffter Research Institute, which funds psychedelic research.
  • Johns Hopkins University Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, supports clinical trials on psilocybin and LSD for addiction at this institution.
  • New York University Partner — Conducted a randomized controlled trial on psilocybin for alcohol use disorder at NYU.
  • State of New York Government — Governing law for the organization's Terms and Conditions.
  • University of Alabama, Birmingham Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, helped fund a placebo-controlled clinical trial of psilocybin for cocaine addiction at this institution.
  • University of New Mexico Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, is planning a study on psilocybin for methamphetamine addiction at this institution.
  • University of Wisconsin Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, funds studies of psilocybin for opioid use disorder at this institution.
  • Yale University Partner — Heffter Research Institute, linked through scientific advisor Dr. Greer, funds research on psilocybin for depression, OCD, and cluster headache at this institution.
  • academic researchers Partner — Collaborates with academic researchers to share information.
  • hello@apollopact.org Partner — Point of contact for participants seeking help identifying appropriate research study contacts.
strategies · 3

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Evidence-Based Public Education
    methodology: evidence_based_public_education
    By disseminating clinically rigorous and accessible information to diverse stakeholders, we produce informed decision-making about psychedelic therapies because education bridges the gap between research and real-world application.
  • Participant-as-Partner in Research
    methodology: participant_as_partner
    By treating clinical trial participants as active collaborators rather than passive subjects, we produce more ethical research and higher engagement because empowerment fosters trust, transparency, and accountability in psychedelic science.
  • Patient-Led Advocacy Model
    methodology: patient_led_advocacy
    By centering leadership and program design on patients and clinical trial participants, we produce more ethical and effective psychedelic therapy policies and practices because lived experience ensures initiatives are grounded in real-world needs and rights.